The Indian Council of Medical Research’s (ICMR) Covid-19 Task Force Joint Monitoring Group has stopped the usage of Hydroxycholoroquine and Ivermectin for treating Covid-19 patients in the nation. Global well being specialists have been warning against the use of these drugs to treat Covid-19, as there was no proof of its therapeutic impact against Covid-19.
These two drugs had been no longer aspect of the revised clinical guidance for management of adult Covid-19 in the nation. The Directorate General of Health Services below the ministry of well being had in May issued suggestions to cease the use of Ivermectin and HCQ and now ICMR has dropped these two drugs. Remdesivir has been recommended for moderate Covid-19 circumstances and Tocilizumab continue to be on the list for extreme Covid circumstances and inside 24-48 hours of the onset of the extreme illness or ICU admission.
As per the new suggestions, therapy for patients with moderate illness with SpO2 level 92-93% and breathlessness has to be with anti-inflammatory and anticoagulation drugs. Remdesivir is to be regarded as only in patients with moderate to extreme illness requiring supplemental oxygen and with no renal or hepatic dysfunction. It is not be utilized in patients who are not on oxygen assistance in home settings.
For the extreme infection with SpO2 level significantly less than 90%, the therapy as per the suggestions is anticoagulation drugs and anti-inflammatory or immunomodulatory therapy. Tocilizumab is to be regarded as if there was no improvement in spite of use of steroids and extreme illness. It is to offered to the patient inside 24 to 48 hours of onset of extreme illness or ICU admission.